AIM

AIM Immunotech Inc. 10-Q Summary: Period Ended June 30, 2026

Business Context and Reporting Period

Company: AIM Immunotech Inc. (AIM)
Reporting Period: Quarter and six months ended June 30, 2026
Business Overview: AIM is an immuno-pharma company focused on developing Ampligen (rintatolimod), a double-stranded RNA molecule, primarily for late-stage pancreatic cancer. The company also holds Alferon N Injection, an FDA-approved natural alpha-interferon for genital warts, though production is currently on hold. AIM is a smaller reporting company and non-accelerated filer.

Key Financial Metrics

Note: Revenue is derived primarily from clinical treatment programs in the US. The company has no material commercial revenue from product sales in the US.

Material Changes vs. Prior Period

• Equity Position: Stockholders' equity improved from a deficit of $(9.8) million at year-end 2025 to $7.7 million at June 30, 2026. This turnaround was driven by significant capital raises and the reclassification of warrant liabilities to equity.
• Liquidity: Cash and cash equivalents increased by 231.7% to $9.9 million, up from $3.0 million at December 31, 2025, due to successful financing activities.
• Expenses:
  • R&D: Decreased 52.5% year-over-year for the six-month period ($1.1M vs $2.3M) due to the suspension of the AMP-270 pancreatic cancer trial and a shift in focus to the DURIPANC study.
  • G&A: Increased 16.7% year-over-year ($4.7M vs $4.0M) primarily due to issuance costs, legal, and accounting fees associated with multiple equity transactions.
• Debt: Interest expense increased significantly (131% for six months) due to new promissory notes with Streeterville Capital LLC.

Guidance, Outlook, and Risks

• Clinical Outlook: The company is focused on the DURIPANC Phase 2 study (Ampligen + Imfinzi) for pancreatic cancer. Enrollment is complete, with topline data expected in Q1 2027. A Phase 3 trial design agreement was signed with Thermo Fisher Scientific in March 2026.
• Capital Raising: AIM completed multiple equity transactions in H1 2026, including a Rights Offering ($1.8M), a Warrant Inducement ($3.6M), and Registered Direct Offerings (Class I and J, totaling ~$5.0M). These actions were critical to regaining NYSE American compliance.
• Listing Compliance: The company successfully resolved NYSE American non-compliance issues regarding stockholders' equity (now >$6M) and low stock price (via a 1-for-100 reverse split in June 2025). The ".BC" indicator was removed on June 12, 2026.
• Risks & Contingencies:
  • Going Concern: Management notes substantial doubt about the ability to continue as a going concern without further financing, despite the recent cash infusion. Operating cash outflows continue to exceed inflows.
  • Dilution: Significant issuance of shares and warrants (approx. 48.5 million warrants outstanding) poses substantial dilution risk.
  • Regulatory: No assurance that clinical trials will yield positive results or lead to FDA approval.

Key Facts for Investor Verification

• Warrant Liability Reclassification: Verify the $8.7 million reclassification of Class E and F warrants from liability to equity following a stock dividend reset, which significantly altered the balance sheet.
• Debt Maturities: Confirm the terms of the Streeterville Capital notes, specifically the current portion of $3.6 million due within 12 months and the extension of maturity dates to 2027.
• Warrant Inducement Costs: Review the accounting treatment of the May 2026 warrant inducement, where $3.6 million of value transferred to holders was recorded as a deemed dividend (reduction of APIC) rather than an expense, impacting EPS but not Net Loss.
• Cash Burn Rate: Assess the sustainability of the $9.9 million cash balance against the estimated annual working capital requirement of $7.2M - $10.8M.
• Patent Portfolio: Note the decision to abandon patents not specific to pancreatic cancer, resulting in a $24k charge in the period, reflecting a strategic pivot.